Hartge DR, Weichert J, Gembicki M, Krapp M. Confirmation of etiology in fetal hydrops by sonographic evaluation of fluid allocation patterns. Eur J Obstet Gynecol. 2015;195:128-132.
Norton ME, Chauhan SP, Dashe JS. Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis. Am J Obstet Gynecol. 2015;212(2):127-139.
Ota S, Sahara J, Mabuchi A, Yamamoto R, Ishii K, Mitsuda N. Perinatal and one-year outcomes of non-immune hydrops fetalis by etiology and age at diagnosis. J Obstet Gynaecol Res. 2015;42(4):385-391.
Bellini C, Fulcheri E, Rutigliani M, et al. Immunohistochemistry in non-immune hydrops fetalis: A single center experience in 79 fetuses. Am J Med Genet. 2010;152A(5):1189-1196.
Liao C, Wei J, Li Q, Li J, Li L, Li D. Nonimmune hydrops fetalis diagnosed during the second half of pregnancy in Southern China. Fetal Diagn Ther. 2007;22(4):302-305.
Derderian SC, Jeanty C, Fleck SR, et al. The many faces of hydrops. J Pediatr Surg. 2015;50(1):50-54.
Boutall A, Urban MF, Stewart C. International Journal of Gynecology and Obstetrics Diagnosis, etiology, and outcome of fetal ascites in a South African hospital. Int J Gynecol Obstet. 2011;115(2):148-152.
Ruano R, Ramalho AS, Karina A, et al. Prenatal diagnosis and natural history of fetuses presenting with pleural effusion. Prenat Diagn. 2011;31(March):496-499.
Santo S, Mansour S, Thilaganathan B, et al. Prenatal diagnosis of non-immune hydrops fetalis: What do we tell the parents? Prenat Diagn. 2011 Feb;31(2):186-195.
Ng ZM, Seet MJ, Erng MN, Buendia F, Chang AS, Sriram B. Nonimmune hydrops fetalis in a children's hospital: A six-year series. Singapore Med J. 2013;54(9):487-490.
Fukushima K, Morokuma S, Fujita Y, et al. Short-term and long-term outcomes of 214 cases of non-immune hydrops fetalis. Early Hum Dev. 2011;87(8):571-575.
Bellini C, Donarini G, Paladini D, et al. Etiology of non-immune hydrops fetalis: An update. Am J Med Genet Part A. 2015;167(5):1082-1088.
Abrams ME, Meredith KS, Kinnard P, Clark RH. Hydrops fetalis: A retrospective review of cases reported to a large national database and identification of risk factors associated with death. Pediatrics. 2007;120(1):84-89.
Czernik C, Proquitté H, Metze B, Bührer C. Hydrops fetalis—has there been a change in diagnostic spectrum and mortality? J Matern Neonatal Med. 2011;24(February):258-263.
Bellini C, Hennekam RCM, Boccardo F, Campisi C, Serra G, Bonioli E. Nonimmune idiopathic hydrops fetalis and congenital lymphatic dysplasia. Am J Med Genet. 2006;140A(7):678-684.
Ghalamkarpour A, Debauche C, Haan E, et al. Sporadic in utero generalized edema caused by mutations in the lymphangiogenic genes VEGFR3 and FOXC2. J Pediatr. 2009;155(1):90-93.
Fotiou E, Martin-Almedina S, Simpson M, et al. Novel mutations in PIEZO1 cause an autosomal recessive generalized lymphatic dysplasia with non-immune hydrops fetalis. Nat Commun. 2015;6:8085.
Lukacs V, Mathur J, Mao R, et al. Impaired PIEZO1 function in patients with a novel autosomal recessive congenital lymphatic dysplasia. Nat Commun. 2015;6:8329.
Beneteau C, Thierry G, Blesson S, et al. Recurrent mutation in the PIEZO1 gene in two families of hereditary xerocytosis with fetal hydrops. Clin Genet. 2014;85(3):293-295.
Connell F, Kalidas K, Ostergaard P, et al. Linkate and sequence analysis indicate that CCBE1 is mutated in recessively inherited generalised lymphatic dysplasia. Hum Genet. 2010;127(2):231-241.
Shah S, Conlin K, Gomez L, et al. CCBE1 mutation in two siblings, one manifesting lymphedema-cholestasis syndrome, and the other, fetal hydrops. PLoS One. 2013;8(9):e75770.
Martin-Almedina S, Martinez-Corral I, Holdhus R, et al. EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic-related hydrops fetalis. J Clin Invest. 2016;126(8):3080-3088.
Fang J, Dagenais SL, Erickson RP, et al. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet. 2010;67(6):1382-1388.
de Bruyn G, Casaer A, Devolder K, et al. Hydrops fetalis and pulmonary lymphangiectasia due to FOXC2 mutation: An autosomal dominant hereditary lymphedema syndrome with variable expression. Eur J Pediatr. 2012;171(3):447-450.
Sargent C, Bauer J, Khalil M, et al. A five generation family with a novel mutation in FOXC2 and lymphedema worsening to hydrops in the youngest generation. Am J Med Genet A. 2014;164A(11):2802-2807.
Daniel-Spiegel E, Ghalamkarpour A, Spiegel R, et al. Hydrops fetalis: An unusual prenatal presentation of hereditary congenital lymphedema. Prenat Diagn. 2005;25(11):1015-1018.
Boudon E, Levy Y, Abossolo T, et al. Antenatal presentation of hereditary lymphedema type I. Eur J Med Genet. 2015;58(6–7):329-331.
Ghalamkarpour A, Morlot S, Raas-Rothschild A, et al. Hereditary lymphedema type I associated with VEGFR3 mutation: The first de novo case and atypical presentations. Clin Genet. 2006;70(4):330-335.
Yang YS, Ma GC, Shih JC, et al. Experimental treatment of bilateral fetal chylothorax using in-utero pleurodesis. Ultrasound Obstet Gynecol. 2012;39(1):56-62.
Irrthum A, Devriendt K, Chitayat D, et al. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet. 2003;72(6):1470-1478.
Ma GC, Liu CS, Chang SP, et al. A recurrent ITGA9 missense mutation in hyman fetuses with severe chylothorax: Possible correlation with poor response to fetal therapy. Prenat Diagn. 2008;28(11):1057-1063.
Croonen EA, Nillesen WM, Stuurman KE, et al. Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings. Eur J Hum Genet. 2013;21(10):936-942.
Simms RA, Liebling RE, Patel RR, et al. Management and outcome of pregnancies with parvovirus B19 infection over seven years in a tertiary fetal medicine unit. Fetal Diagn Ther. 2009;25(4):373-378.
